Slide 1: ASX Announcement: Investor Presentation – Bioshares Biotech Summit
Acrux Limited (ACR:ASX) ASX Announcement 6 August 2026 Investor Presentation – Bioshares Biotech Summit Today our CEO and Managing Director, John Warmbrunn, is presenting at Bioshare’s 20th Biotech Summit. A copy of this Investor Presentation which has a clear focus on Female Testosterone accompanie
Slide 2: Healthspan
Healthspan John Warmbrunn CEO & Managing Director Acrux Ltd August 2026 Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026
Slide 3: Disclaimer
Disclaimer 2 This presentation contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and
Slide 4: Low Libido and Healthspan
LOW LIBIDO and HEALTHSPAN 3 Illustrative diagram only Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026
Slide 5: What is Hypoactive Sexual Desire Disorder (HSDD)?
What is Hypoactive Sexual Desire Disorder (HSDD)? 4 Commonly expressed as low or absent sexual desire and/or response to stimulation ~4.9m Other symptoms include: menopausal women in the US affected Low self- Reduced Social esteem energy conflict ~10% of all adult women impacted Depression Anxiety R
Slide 6: HSDD impacts more than desire
HSDD impacts more than desire SEXUAL HEALTH 5 Desire – Intimacy - Satisfaction RELATIONSHIP HEALTH Connection – Communication - Closeness EMMOTIONAL WELL- It touches every BEING part of a Mood – Stress – Mental wellness women’s well QUALITY OF LIFE being Fulfilment – Happiness – Life satisfaction SE
Slide 7: Testosterone is not simply a male hormone but is also important in women
Testosterone is not simply a male hormone but is also an important hormone in women. Low sexual desire is the most prevalent sexual concern amongst women. When sufficient to cause personal distress women are considered as having hypoactive sexual desire dysfunction or HSDD. There is irrefutable evid
Slide 8: Significant Global Market Opportunity
Significant Global Market Opportunity 7 Estimated US & EU HSDD Market Potential Global Population for ~60m Potential p.a. (US$B) Female Testosterone* women in the US estimated HSDD postmenopausal to be affected by menopause 65+ years Alzheimer's / women $4.54 45% 18-44 cognitive decline years 28% $7
Slide 9: Female Testosterone MDTS
Acrux Ltd (ASX:ACR) Female Testosterone MDTS Helping millions of women with Hypoactive Sexual Desire Disorder (HSDD) Bioshares Biotech Summit | 6 August 2026
Slide 10: Testosterone: A Transformative Opportunity in Women's Health
Testosterone: A Transformative Opportunity in Women's Health 9 Core Indication HSDD HSDD is the primary clinical application for testosterone therapy in women, serving as the foundation of treatment. Potential beyond HSDD • Sexual Health Spectrum Testosterone influences multiple aspects of female se
Slide 11: Female Testosterone MDTS: Blockbuster potential
01 Female Testosterone MDTS Blockbuster potential Acrux Ltd (ASX:ACR)
Slide 12: Acrux History
Acrux History 11 1998: Acrux incorporated to 2003: commercialise unique Recuvyra® 2007: 2016: drug delivery Veterinary product Evamist® licensed to Lenzetto® launched 2024: 2025: technology invented at licensed to Elanco KV Pharmaceutical in Europe by Gedeon Launch Dapsone Launch Dapsone Monash Univ
Slide 13: Acrux Proven MDTS Technology
Acrux Proven MDTS Technology 12 No alternative competitor Applicator launched in 18 years Proprietary MDTS (Metered Dose Transdermal System) Applicator Delivers a controlled spray of Female Testosterone through the skin Patchless Patch forms an invisible reservoir within the skin Lenzetto® and Evami
Slide 14: Female Testosterone Awareness
Female Testosterone Awareness 13 Female Testosterone is gaining significant mainstream patient population awareness and traction across key global markets. Acrux Ltd (ASX:ACR) | Bioshares Biotech Summit | 6 August 2026
Slide 15: Global Positioning of Testosterone Therapy for Women
Global Positioning of Testosterone Therapy for Women 14 FDA “Black box" warnings: First evidence-based GCS noted an unmet medical need On hormone therapy Safety & Efficacy : guidelines: For for a testosterone transdermal products for over 20 years, Inconsistent treatment testosterone therapy in prod
Slide 16: Phase III Study
02 Phase III Study Development roadmap in place Acrux Ltd (ASX:ACR)
Slide 17: Clear Phase II Results
Clear Phase II Results 16 Number of Satisfactory Sexual Events: • Mean number of satisfactory sexual Change from Baseline events increased compared to placebo at 3.0 weeks 4, 8, 12 and 16 for all of the testosterone groups. 2.5 • Statistically significant increase in the 2.0 primary endpoint in the
Slide 18: Phase III Pivotal Clinical Trial Design - A Critical Next Step
Phase III Pivotal Clinical Trial Design - A Critical Next Step 17 USA Study Design A Phase III, Double-Blind, Placebo Controlled FDA Pre-IND recent Study of the Safety and Efficacy of feedback Testosterone Transdermal Spray for the Title FDA Post end-of-Phase-II Treatment of Sexual Dysfunction (Hypo
Slide 19: Lifecycle Strategy for Further Development
Lifecycle Strategy for Further Development 18 Expand proposed indication/ New improved MDTS population to include: MDTS Companion applicator with patent Smartphone App • Female sexual interest/arousal protection disorder (FSIAD) • Female sexual arousal disorder (FSAD) • Women with premature menopaus
Slide 20: Development Roadmap
03 Development Roadmap Close to market - Clear regulatory pathway Acrux Ltd (ASX:ACR)
Slide 21: Co-development Roadmap
Co-development Roadmap 20 Multiple near-term and medium-term milestones will ensure strong investor engagement and catalysts through to product launch in the US in 2019 • Focus is on progressing potential co-development partnerships in 2026 2027 2028 2029 2030 the near-term to de-risk the clinical C
Slide 22: Female Testosterone MDTS
Acrux Ltd (ASX:ACR) Female Testosterone MDTS Helping millions of women with Hypoactive Sexual Desire Disorder (HSDD) Bioshares Biotech Summit | 6 August 2026
Slide 23: Female Testosterone MDTS catalyses Acrux's investment proposition
Female Testosterone MDTS catalyses Acrux’s investment proposition 22 Phase III stage asset. Significant, fast-growing market. Helping millions of women with Early mover advantage. Hypoactive Sexual Desire Disorder (HSDD) Patient preferred application. Co-development pathway. Acrux Ltd (ASX:ACR) | Bi
Slide 24: Pooled Development Fund
Pooled Development Fund 23 Purpose Benefits • Pooled Development Fund Capital gains made by PDF Act 1992 was established by shareholders are not the Federal Government taxable • Increase the supply of Shareholders can elect to capital to Australian small treat dividends paid by a and medium-size
Slide 25: Successful development and FDA registration of topical pharmaceuticals generates core Acrux income
Successful development and FDA registration of topical pharmaceuticals 24 generates core Acrux income FDA registered products commercialised in the US License revenues from Generic portfolio • Nitroglycerin 0.4% ointment launched. 4 Q1 Q2 Q3 Q4 • Dapsone 5.0% gel launched. 3.5 Includes $1.35M • Daps
Slide 26: Thank you
Acrux Ltd (ASX:ACR) THANKYOU Questions Bioshares Biotech Summit | 6 August 2026